Redeye welcomes the continued commercial orders for NeoDynamics in Germany and Switzerland. We believe that its ramp-up awaits the lift of corona-related restrictions but are encouraged by its efforts and successes in introducing NeoNavia to prolific breast cancer centers. In addition to its activities in the European market, we anticipate an FDA filing before year-end that could open up the doors for the much bigger US market. Today’s news does not render any changes to our current Base Case, which stands at SEK 4 per share.